EUVIMEDEUVIMED entdecken
Crossref

Establishment and Characterization of Patient‐Derived Xenograft Organoids for Personalized Treatment of Castration‐Resistant Prostate Cancer

Takuro Sunada iD, Yuki Kamiyama, Maki Fujiwara, Kensuke Hikami, Arinobu Fukunaga, Tomohiro Fukui iD, Kei Mizuno, Kosuke Okasho, Yuki Kita, Takayuki Sumiyoshi, Kimihiko Masui iD, Ryoichi Saito iD und 4 weitere

The Prostate · 2026-07 · 86 (10) · 1134-1149

DOI: 10.1002/pros.70192 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, online erschienen am 07.05.2026. Verfasst von Takuro Sunada und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. Hauptthemen laut MEDLINE: Organoids, Prostatic Neoplasms, Castration-Resistant, Precision Medicine, Xenograft Model Antitumor Assays. Die Arbeit nennt 55 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Basic research on castration‐resistant prostate cancer (CRPC) is limited by the lack of clinically relevant models. This study aimed to establish patient‐derived xenografts (PDX) and PDX‐derived organoids from clinical CRPC specimens to develop a bidirectional experimental platform for in vivo xenografts and ex vivo organoids.

Methods

We established a new PDX library (KUCaP PDX series) using CRPC clinical specimens and derived prostate cancer organoids. Comprehensive biological characterization of clinical specimens, PDXs, PDX‐derived organoids, and organoid‐derived xenografts (ODXs) was performed to confirm the preservation of the original tumor features. Using our PDX library, we conducted genetic engineering and drug testing to explore novel therapeutic approaches.

Results

PDX‐derived organoids were successfully established from all eight KUCaP PDX lines (100%). Four of the eight lines (50%) were maintained during the long‐term culture experiments for over ten passages. Key features observed in the original clinical specimens, including genetic alterations and castration responsiveness, were maintained across the PDX, PDX‐derived organoid, and ODX models. RNA sequencing revealed that transcriptomic profiles were consistently maintained across clinical specimens, PDXs, PDX‐derived organoids, and ODXs. One PDX and organoid (KUCaP19) which exhibited a high homologous recombination deficiency (HRD) score, without any pathogenic homologous recombination repair (HRR) gene alterations, showed sensitivity to a poly ADP‐ribose polymerase (PARP) inhibitor. In contrast, KUCaP12, which had no HRR alterations and a low HRD score, did not respond to PARP inhibition.

Conclusions

We developed the KUCaP library as a novel experimental platform for CRPC research by integrating clinical specimens with PDX, organoid, and ODX models along with their genomic and transcriptomic data. These models largely retained the genetic profiles and responses to castration observed in the original tumors. The bidirectional use of personalized PDX and organoids will facilitate the elucidation of the molecular mechanisms of CRPC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OrganoidsProstatic Neoplasms, Castration-ResistantPrecision MedicineXenograft Model Antitumor AssaysMaleHumansAnimalsMiceHeterografts

Stichwörter der Autor:innen

castration‐resistant prostate cancerdrug testingorganoidpersonalized treatmentxenograft

Autor:innen und Institutionen

  • Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

ORCID-Profile: Takuro Sunada, Tomohiro Fukui, Kimihiko Masui, Ryoichi Saito, Takashi Kobayashi

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Sunada, T., Kamiyama, Y., Fujiwara, M., Hikami, K., Fukunaga, A., Fukui, T., Mizuno, K., Okasho, K., Kita, Y., Sumiyoshi, T., Masui, K., Saito, R., Akamatsu, S., Ogawa, O., Kobayashi, T., & Goto, T. (2026). Establishment and Characterization of Patient‐Derived Xenograft Organoids for Personalized Treatment of Castration‐Resistant Prostate Cancer. The Prostate, 86(10), 1134-1149. https://doi.org/10.1002/pros.70192

Vancouver

Sunada T, Kamiyama Y, Fujiwara M, Hikami K, Fukunaga A, Fukui T, et al. Establishment and Characterization of Patient‐Derived Xenograft Organoids for Personalized Treatment of Castration‐Resistant Prostate Cancer. The Prostate. 2026;86(10):1134-1149. doi:10.1002/pros.70192

BibTeX
@article{Sunada2026,
  author = {Sunada, Takuro and Kamiyama, Yuki and Fujiwara, Maki and Hikami, Kensuke and Fukunaga, Arinobu and Fukui, Tomohiro and Mizuno, Kei and Okasho, Kosuke and Kita, Yuki and Sumiyoshi, Takayuki and Masui, Kimihiko and Saito, Ryoichi and Akamatsu, Shusuke and Ogawa, Osamu and Kobayashi, Takashi and Goto, Takayuki},
  title = {Establishment and Characterization of Patient‐Derived Xenograft Organoids for Personalized Treatment of Castration‐Resistant Prostate Cancer},
  journal = {The Prostate},
  year = {2026},
  volume = {86},
  number = {10},
  pages = {1134--1149},
  doi = {10.1002/pros.70192}
}
Kostenlos starten →